FDA Assigns Class II Recall to 2.5 Million Cataract Surgery Eye Drop Vials Over Contamination Concerns

Millions of prescription eye drop vials commonly used after cataract surgery have been voluntarily recalled across the United States after concerns that some products could contain a foreign substance. The U.S. Food and Drug Administration has classified the action as a Class II recall, indicating that use of the affected product could result in temporary or medically reversible health effects if contamination is present.

The recall involves Prednisolone Acetate Ophthalmic Suspension USP, 1%, a corticosteroid eye drop that is routinely prescribed after cataract surgery and other eye procedures to reduce inflammation and promote healing. Lupin Pharmaceuticals Inc., based in Naples, Florida, initiated the voluntary recall after identifying a potential quality issue involving foreign material in certain batches manufactured by Lupin Limited in India.

According to the FDA enforcement report, approximately 2,530,182 eye drop vials are included in the recall. The affected products were distributed nationwide in 5 mL, 10 mL, and 15 mL bottles. Patients who recently underwent cataract surgery or who use prednisolone acetate for inflammatory eye conditions are encouraged to verify whether their prescription is part of the recall.

Why the Eye Drops Were Recalled

The recall was initiated after concerns emerged that some bottles could contain a foreign substance. Although the manufacturer has not publicly identified the exact nature of the material, the possibility of contamination prompted the company to voluntarily remove the affected products from the market.

Foreign particles in sterile ophthalmic products can present safety concerns because the medication is applied directly to the eye. Depending on the size and composition of the material, contamination could potentially cause irritation, inflammation, discomfort, or other temporary complications. The voluntary recall is intended to prevent patients from using any potentially affected products while the issue is investigated.

Importantly, the FDA has not reported any confirmed injuries or adverse events linked to the recalled eye drops as of the latest update.

FDA Issues Class II Recall Classification

The FDA officially designated the recall as a Class II recall on June 30 after Lupin initiated the voluntary action on June 4.

A Class II recall is the agency's second highest recall classification. It is used when exposure to a product may cause temporary or medically reversible adverse health consequences, or when the probability of serious health consequences is considered remote.

For comparison, FDA recall classifications include:

• Class I: Products that have a reasonable probability of causing serious injury or death.
• Class II: Products that may cause temporary or medically reversible health effects or carry a remote chance of serious harm.
• Class III: Products that violate FDA regulations but are unlikely to cause adverse health effects.

A Class II designation does not necessarily mean patients who used the medication will experience complications. Instead, it reflects the potential level of risk if the product is defective.

Why Prednisolone Eye Drops Are Commonly Prescribed

Prednisolone acetate ophthalmic suspension is among the most frequently prescribed steroid eye drops in the United States. Ophthalmologists use it to reduce inflammation following eye surgery and to treat several inflammatory eye diseases.

After cataract surgery, inflammation is a normal part of the healing process. Corticosteroid eye drops help control swelling, reduce discomfort, and lower the risk of complications that could affect vision during recovery.

The medication is also prescribed for conditions such as:

• Iritis
• Uveitis
• Other inflammatory disorders affecting the iris and surrounding structures of the eye
• Post-operative inflammation after various ophthalmic procedures

Because of its effectiveness, prednisolone acetate remains a standard treatment used by eye specialists nationwide.

Eye Specialists Respond to the Recall

Eye care experts have emphasized that the recall reflects the effectiveness of pharmaceutical quality monitoring rather than evidence of widespread patient harm.

According to ophthalmologists at the UC Davis Eye Center, prednisolone acetate is routinely prescribed after cataract surgery and remains an important medication in post-operative care.

Clinical experts also noted that recalls such as this are part of standard quality control procedures designed to identify potential manufacturing issues before they result in widespread patient injuries.

Since no adverse events have been reported, physicians continue to recommend that patients follow their doctor's instructions rather than discontinue treatment on their own.

What Patients Should Do

Patients should check the manufacturer and lot information on their prescription bottle to determine whether it is included in the recall. Individuals should not stop using prescribed medication without consulting their healthcare provider, particularly if they recently underwent cataract surgery.

If an affected bottle is identified, patients should contact the prescribing ophthalmologist, optometrist, pharmacist, or healthcare provider to obtain a replacement medication or receive guidance on the next appropriate step.

Patients who experience symptoms such as increased eye pain, redness, blurred vision, unusual discharge, swelling, or worsening irritation after using any eye medication should seek prompt medical evaluation.

Healthcare providers can determine whether symptoms are related to surgery, infection, inflammation, or another cause requiring treatment.

Recall Highlights

Here are the key details patients should know:

• Product: Prednisolone Acetate Ophthalmic Suspension USP, 1%
• Manufacturer: Lupin Limited (India)
• Distributor: Lupin Pharmaceuticals Inc., Naples, Florida
• Recall initiated: June 4, 2026
• FDA Class II designation: June 30, 2026
• Bottles recalled: Approximately 2.53 million
• Sizes affected: 5 mL, 10 mL, and 15 mL
• Distribution: Nationwide across the United States
• Reason: Potential foreign substance contamination
• Reported injuries: None reported at the time of the FDA announcement

Patients who are uncertain whether their medication is included should contact their pharmacy or prescribing physician for verification.

The Bottom Line

The FDA's Class II recall of more than 2.5 million prednisolone acetate eye drop vials highlights the importance of pharmaceutical quality monitoring and patient safety. While the recall involves a medication that is widely prescribed after cataract surgery and for inflammatory eye diseases, there have been no reported injuries associated with the affected products.

Patients should avoid making changes to their treatment plan without medical advice. Instead, they should verify whether their medication is included in the recall and consult their healthcare provider if a replacement is needed. Prompt communication with a physician helps ensure continued treatment while minimizing any potential risks associated with the recalled product.

Sources

• U.S. Food and Drug Administration (FDA) Enforcement Report
• Lupin Pharmaceuticals Inc. voluntary recall announcement
• UC Davis Eye Center statements from Dr. Jeffrey H. Ma and Dr. Gary Novack

Disclaimer

This article is for informational and educational purposes only and should not be considered medical advice. Always consult your physician, ophthalmologist, pharmacist, or another qualified healthcare professional before stopping, replacing, or changing any prescribed medication. If you believe you have experienced an adverse reaction after using an eye medication, seek medical care promptly.